News

Stay up-to-date on the latest news from PBM Capital and its portfolio companies

04.04.2024 Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer 

03.26.2024 Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA  

02.29.2024 Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome

02.13.2024 CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma

01.10.2024 Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome 

01.03.2024 Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH™

12.08.2023 UVA Breaks Ground on Paul and Diane Manning Institute of Biotechnology

01.30.2023 UVA Lands $100 Million From Paul and Diane Manning for New Biotech Institute 

09.24.2020 Taysha Gene Therapies Announces Pricing of Initial Public Offering

06.22.2020 ArcherDx to be Acquired by Invitae in ~$1.4B Stock and Cash Transaction

04.29.2020 Taysha Gene Therapies Launches with $30 Million Seed Financing Led by PBM Capital

01.08.2020 ​ Candel Therapeutics Acquires Next-Generation Viral Immunotherapy Platform and Manufacturing Expertise

11.27.2019 Verrica Pharmaceuticals Announces FDA Filing Acceptance of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

09.30.2019 Dova Pharmaceuticals To Be Acquired By Swedish Orphan Biovitrum AB (SOBI)

01.04.2019
Candel Therapeutics Completes $28.7 Million Series B Financing

01.04.2019
Candel Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

12.07.2018
LaunchPad Ignites Breakthroughs in Diabetes